Dr. Reddy

Pharma major Dr. Reddy’s Laboratories, for which Russia and CIS region count among important, growth markets, is closely monitoring developments amid the escalating tensions between Ukraine and Russia.“We have been monitoring developments…

Stocks of Indian companies with exposure to Europe fell on Tuesday amid concerns about the impact on their sales in case the Russia-Ukraine crisis worsens and the US and its allies impose economic sanctions on Russia. IMAGE: Activists hold…

Investors' wealth on Thursday tumbled over Rs 2.81 lakh crore as stocks declined in line with selloff in global equities. The 30-share BSE benchmark index tanked 581.21 points or 1 per cent to settle at 57,276.94. During the day, it…

'This fall is nothing. We could see worse if everybody hits the panic button.' IMAGE: An investor reacts to falling stockmarket numbers. Kindly note the image has only been posted for representational purposes. Photograph: ANI Photo…

Bajaj Finserv was the top loser in the Sensex pack, shedding 4.57 per cent, followed by Infosys, TCS, Sun Pharma, HCL Tech, HUL, Dr Reddy's, HDFC and Reliance Industries. NSE Nifty plunged 181.40 points to 17,757.00. Falling for the third…

Earlier this year, the drug major entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs). (File…

On the Sensex chart, major gainers were NTPC, PowerGrid, SBI, Titan, Reliance, Bajaj Finance and Axis Bank, rising as much as 5.48 per cent. NSE Nifty rose 179.55 points to end at 17,805.25. The BSE Sensex surged by 673 points and the…

Dr. Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.…